Niacin controlled release/laropiprant - Merck

Drug Profile

Niacin controlled release/laropiprant - Merck

Alternative Names: Cordaptive; ER niacin/laropiprant; ERN/LRPT - Merck; Extended-release niacin/immediate-release laropiprant; Laropiprant/ER niacin; Laropiprant/extended-release niacin; Laropiprant/nicotinic acid; MK-0524A; MK-524A; Nicotinic acid/laropiprant; Pelzont; Tredaptive; Tredaptive Extended-release tab; Trevaclyn

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; Merck Sharp & Dohme
  • Class Antihyperlipidaemics; Indoles; Nicotinic-acids; Small molecules
  • Mechanism of Action GPR109A receptor agonists; GPR109B receptor agonists; Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Dyslipidaemias; Hypercholesterolaemia
  • Discontinued Atherosclerosis

Most Recent Events

  • 06 Aug 2013 Biomarkers information updated
  • 09 Mar 2013 Withdrawn for Dyslipidaemias in Hong Kong (PO)
  • 09 Mar 2013 Withdrawn for Dyslipidaemias in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top